Skip to main content

Back

Publications

Orphan Drug Designation for Treatment of Autosomal Dominant Polycystic Kidney Disease

Orphan Drug Designation for Treatment of Autosomal Dominant Polycystic Kidney Disease

Progeria

Progeria

Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

FDA Grants J&D Pharmaceuticals Rare Pediatric Disease Designation and Orphan Drug Designation

FDA Grants J&D Pharmaceuticals Rare Pediatric Disease Designation and Orphan Drug Designation

History and Development of the Salicylates

History and Development of the Salicylates

Molecular Mechanism of action of JD-005

Molecular Mechanism of action of JD-005

JD-004 improves TBI outcomes in the rodent model

JD-004 improves TBI outcomes in the rodent model

PC Reduces NSAID-Induced GI Toxicity

PC Reduces NSAID-Induced GI Toxicity

The Role of JD-005 in TBI: Targeting Acetylated Tau

The Role of JD-005 in TBI: Targeting Acetylated Tau

JD-004, Placebo, and Aspirin Comparison

JD-004, Placebo, and Aspirin Comparison

Interested in learning more?

Contact Us